These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37402738)

  • 1. The engineered single guide RNA structure as a biomarker for gene-editing reagent exposure.
    Ryan EC; Huggins LM; Podlevsky JD
    Sci Rep; 2023 Jul; 13(1):10804. PubMed ID: 37402738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Guide RNAs: A Glimpse at the Sequences that Drive CRISPR-Cas Systems.
    Briner AE; Barrangou R
    Cold Spring Harb Protoc; 2016 Jul; 2016(7):. PubMed ID: 27371605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Advances in the RNA-targeting CRISPR-Cas systems].
    Hong T; Luo Q
    Sheng Wu Gong Cheng Xue Bao; 2023 Apr; 39(4):1363-1373. PubMed ID: 37154311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems.
    Chylinski K; Le Rhun A; Charpentier E
    RNA Biol; 2013 May; 10(5):726-37. PubMed ID: 23563642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation.
    Liu TY; Doudna JA
    J Biol Chem; 2020 Oct; 295(42):14473-14487. PubMed ID: 32817336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tracrRNA in CRISPR Biology and Technologies.
    Liao C; Beisel CL
    Annu Rev Genet; 2021 Nov; 55():161-181. PubMed ID: 34416117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The structural biology of type III CRISPR-Cas systems.
    Li X; Han J; Yang J; Zhang H
    J Struct Biol; 2024 Mar; 216(1):108070. PubMed ID: 38395113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biogenesis pathways of RNA guides in archaeal and bacterial CRISPR-Cas adaptive immunity.
    Charpentier E; Richter H; van der Oost J; White MF
    FEMS Microbiol Rev; 2015 May; 39(3):428-41. PubMed ID: 25994611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterizing the activity of abundant, diverse and active CRISPR-Cas systems in lactobacilli.
    Crawley AB; Henriksen ED; Stout E; Brandt K; Barrangou R
    Sci Rep; 2018 Aug; 8(1):11544. PubMed ID: 30068963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient CRISPR editing with a hypercompact Cas12f1 and engineered guide RNAs delivered by adeno-associated virus.
    Kim DY; Lee JM; Moon SB; Chin HJ; Park S; Lim Y; Kim D; Koo T; Ko JH; Kim YS
    Nat Biotechnol; 2022 Jan; 40(1):94-102. PubMed ID: 34475560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-cas spacers in orphan CRISPR4 arrays prevent uptake of active CRISPR-Cas I-F systems.
    Almendros C; Guzmán NM; García-Martínez J; Mojica FJ
    Nat Microbiol; 2016 Jun; 1(8):16081. PubMed ID: 27573106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Orthogonal CRISPR/dCas12a System for RNA Imaging in Live Cells.
    Jia HY; Zhang XY; Ye BC; Yin BC
    Anal Chem; 2024 Apr; 96(15):5913-5921. PubMed ID: 38563119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Multiplex gene editing and regulation techniques based on CRISPR/Cas system].
    Fan X; Wang J; Liang L; Liu R
    Sheng Wu Gong Cheng Xue Bao; 2023 Jun; 39(6):2449-2464. PubMed ID: 37401603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Origins and evolution of CRISPR-Cas systems.
    Koonin EV; Makarova KS
    Philos Trans R Soc Lond B Biol Sci; 2019 May; 374(1772):20180087. PubMed ID: 30905284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR-Cas System: The Powerful Modulator of Accessory Genomes in Prokaryotes.
    Butiuc-Keul A; Farkas A; Carpa R; Iordache D
    Microb Physiol; 2022; 32(1-2):2-17. PubMed ID: 34192695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diverse Mechanisms of CRISPR-Cas9 Inhibition by Type II Anti-CRISPR Proteins.
    Hwang S; Maxwell KL
    J Mol Biol; 2023 Apr; 435(7):168041. PubMed ID: 36893938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment.
    Kennedy EM; Cullen BR
    Virology; 2015 May; 479-480():213-20. PubMed ID: 25759096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR-Cas System: History and Prospects as a Genome Editing Tool in Microorganisms.
    Javed MR; Sadaf M; Ahmed T; Jamil A; Nawaz M; Abbas H; Ijaz A
    Curr Microbiol; 2018 Dec; 75(12):1675-1683. PubMed ID: 30078067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and applications of Type I CRISPR-Cas systems.
    Hidalgo-Cantabrana C; Barrangou R
    Biochem Soc Trans; 2020 Feb; 48(1):15-23. PubMed ID: 31922192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reprogrammed tracrRNAs enable repurposing of RNAs as crRNAs and sequence-specific RNA biosensors.
    Liu Y; Pinto F; Wan X; Yang Z; Peng S; Li M; Cooper JM; Xie Z; French CE; Wang B
    Nat Commun; 2022 Apr; 13(1):1937. PubMed ID: 35410423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.